Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-2 modified Renca cells
- Development stage
- Preclinical
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Interleukin-2 modified Renca cells are a type of tumor vaccine consisting of Renca renal cell carcinoma cells genetically engineered to express and produce interleukin-2 (IL-2). These modified cells are used in preclinical studies, specifically in a mouse model of pulmonary metastasis, to elicit an antitumor immune response. The production of IL-2 by the tumor cells aims to enhance local and systemic immunity against the tumor, and has shown synergistic effects when combined with local radiation therapy.
- Other names
- Renca/IL-2
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on interleukin-2 modified Renca cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-2 modified Renca cells.